MIRA
INFORM REPORT
|
Report Date : |
01.03.2014 |
IDENTIFICATION DETAILS
|
Name : |
CHONG KUN DANG PHARMACEUTICAL CORP |
|
|
|
|
Registered Office : |
Chongkundang
Bldg., 368, Chungjeongno 3-Ga,
Seodaemun-Gu |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
05.11.2013 |
|
|
|
|
Legal Form : |
Public Parent
Company |
|
|
|
|
Line of Business : |
Manufacturer, distributor, exporter and importer
of pharmaceutical preparations, including vaccines Subject operates its business through research,
development, manufacture and distribution of pharmaceuticals. Subject main products portfolio consists of
prescription drugs, including granisetron hydrochloride, orlistat,
montelukast sodium, rivotril tablets, tamiflu capsules, valcyte tablets,
copregrel capsules, isosorbide mononitrate and others, as well as over the
counter (OTC) drugs, including trichophyton, pityrosporum orbiculare |
|
|
|
|
No. of Employees : |
1,473 |
RATING & COMMENTS
|
MIRA’s Rating : |
NB |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
-- |
NB |
New Business |
-- |
|
Status : |
New Business |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – december 01, 2013
|
Country Name |
Previous Rating (30.09.2013) |
Current Rating (01.12.2013) |
|
South Korea |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
South Korea ECONOMIC OVERVIEW
South Korea
over the past four decades has demonstrated incredible growth and global
integration to become a high-tech industrialized economy. In the 1960s, GDP per
capita was comparable with levels in the poorer countries of Africa and Asia.
In 2004, South Korea joined the trillion dollar club of world economies, and is
currently the world's 12th largest economy. Initially, a system of close government
and business ties, including directed credit and import restrictions, made this
success possible. The government promoted the import of raw materials and
technology at the expense of consumer goods, and encouraged savings and
investment over consumption. The Asian financial crisis of 1997-98 exposed
longstanding weaknesses in South Korea's development model including high
debt/equity ratios and massive short-term foreign borrowing. GDP plunged by
6.9% in 1998, and then recovered by 9% in 1999-2000. Korea adopted numerous
economic reforms following the crisis, including greater openness to foreign
investment and imports. Growth moderated to about 4% annually between 2003 and
2007. Korea''s export focused economy was hit hard by the 2008 global economic
downturn, but quickly rebounded in subsequent years, reaching 6.3% growth in
2010. The US-South Korea Free Trade Agreement was ratified by both governments
in 2011 and went into effect in March 2012. Throughout 2012 the economy
experienced sluggish growth because of market slowdowns in the United States,
China, and the Eurozone. The incoming administration in 2013, following the
December 2012 presidential election, is likely to face the challenges of
balancing heavy reliance on exports with developing domestic-oriented sectors,
such as services. The South Korean economy''s long term challenges include a
rapidly aging population, inflexible labor market, and heavy reliance on
exports - which comprise half of GDP.
|
Source : CIA |
Company name
& address
Chong Kun Dang
Pharmaceutical Corp
Chongkundang
Bldg.,
368, Chungjeongno
3-Ga, Seodaemun-Gu
Seoul, 120756
Korea, Republic
of
Tel: 82-2-21940300
Fax: 82-2-21940369
Web: www.ckdpharm.com
synthesis
Employees: 1,473
Company Type: Public
Parent
Corporate Family: 4 Companies
Traded: Korea Stock Exchange: 185750
Incorporation
Date: 05-Nov-2013
Financials in: Usd (Millions)
Fiscal Year End: 31-Dec-2012
Reporting Currency: South
Korean Won
Annual Sales:
NA
Total Assets:
NA
Market Value:
653.0 (10-Jan-2014)
Business
Description
Chong Kun Dang Pharmaceutical Corp. is Korea-based
company mainly engaged in the pharmaceutical business. The Company operates its
business through research, development, manufacture and distribution of
pharmaceuticals. The Company’s main products portfolio consists of
prescription drugs, including granisetron hydrochloride, orlistat, montelukast
sodium, rivotril tablets, tamiflu capsules, valcyte tablets, copregrel
capsules, isosorbide mononitrate and others, as well as over the counter (OTC)
drugs, including trichophyton, pityrosporum orbiculare and others. Its products
are applied for treatment of high blood pressure, leukemia, dermatitis, anemia,
dyspepsia, gastric ulcer, influenza, infection, diabetes. In addition, it
provides vitamin and other products. Chong Kun Dang Pharmaceutical Corp has not
disclosed any comparable financial information.
Industry
Industry
Pharmaceutical Manufacturing
ANZSIC 2006: 1841 - Human Pharmaceutical and Medicinal
Product Manufacturing
ISIC Rev 4: 2100 - Manufacture of pharmaceuticals,
medicinal chemical and botanical products
NACE Rev 2: 2120 - Manufacture of pharmaceutical
preparations
NAICS 2012: 325412 - Pharmaceutical Preparation
Manufacturing
UK SIC 2007: 2120 - Manufacture of pharmaceutical
preparations
US SIC 1987: 2834 - Pharmaceutical Preparations
Key Executives
|
Name |
Title |
|
Jeong Woo Kim |
Vice President |
|
Tae Young Kim |
Finance Head |
|
Jang Han Lee |
Chairman |
|
Jang Han Rhee |
Chairman |
Stock Snapshot
|
1 - Profit &
Loss Item Exchange Rate: USD 1 = KRW 1126.849
2 - Balance Sheet
Item Exchange Rate: USD 1 = KRW 1066.4
Corporate
Overview
Location
Chongkundang
Bldg.
, 368,
Chungjeongno 3-Ga, Seodaemun-Gu
Seoul, 120756
Korea, Republic
of
Tel: 82-2-21940300
Fax: 82-2-21940369
Web: www.ckdpharm.com
Quote Symbol -
Exchange
185750 - Korea Stock Exchange
Sales KRW(mil): NA
Assets KRW(mil): NA
Employees: 1,473
Fiscal Year End: 31-Dec-2012
Industry: Biotechnology and Drugs
Incorporation
Date: 05-Nov-2013
Company Type: Public Parent
Quoted Status: Quoted
Vice President: Jeong Woo Kim
Industry Codes
ANZSIC 2006
Codes:
1841 - Human
Pharmaceutical and Medicinal Product Manufacturing
ISIC Rev 4 Codes:
2100 - Manufacture
of pharmaceuticals, medicinal chemical and botanical products
NACE Rev 2 Codes:
2120 - Manufacture
of pharmaceutical preparations
NAICS 2012 Codes:
325412 - Pharmaceutical
Preparation Manufacturing
US SIC 1987:
2834 - Pharmaceutical
Preparations
UK SIC 2007:
2120 - Manufacture
of pharmaceutical preparations
Business Description
Chong Kun Dang
Pharmaceutical Corp. is Korea-based company mainly engaged in the
pharmaceutical business. The Company operates its business through research,
development, manufacture and distribution of pharmaceuticals. The Company’s
main products portfolio consists of prescription drugs, including granisetron
hydrochloride, orlistat, montelukast sodium, rivotril tablets, tamiflu
capsules, valcyte tablets, copregrel capsules, isosorbide mononitrate and
others, as well as over the counter (OTC) drugs, including trichophyton,
pityrosporum orbiculare and others. Its products are applied for treatment of
high blood pressure, leukemia, dermatitis, anemia, dyspepsia, gastric ulcer,
influenza, infection, diabetes and others. In addition, it provides vitamin and
other products. Chong Kun Dang Pharmaceutical Corp has not disclosed any
comparable financial information.
More Business Descriptions
Manufacture,
distribution, export and import of pharmaceutical preparations, including
vaccines
Pharmaceutical
Product Mfr
Pharmaceutical
and Medicine Manufacturing
|
|||||||||||||||||||||||
|
Corporate Family |
Corporate
Structure News: |
|
|
Chong
Kun Dang Pharmaceutical Corp |
|
Chong Kun Dang Pharmaceutical Corp |
|
|
Company
Name |
Company
Type |
Location |
Country |
Industry |
Sales |
Employees |
|
|
Chong Kun Dang Pharmaceutical
Corp |
Parent |
Seoul |
Korea, Republic of |
Pharmaceutical Manufacturing |
|
1,473 |
|
|
Kyongbo Pharmaceutical Co.,
Ltd. |
Subsidiary |
Asan, Chungchongnam-Do |
Korea, Republic of |
Pharmaceutical Manufacturing |
137.9 |
242 |
|
|
Ansung Precision Machinery
Co., Ltd. |
Subsidiary |
Hwasong, Kyonggi-Do |
Korea, Republic of |
Machinery and Equipment Manufacturing |
|
40 |
|
|
La Joie Corp |
Subsidiary |
Seoul |
Korea, Republic of |
Nonclassifiable Establishments |
|
40 |
|
Competitors Report
|
Company Name |
Location |
Employees |
Ownership |
|
Aventis Pharma Ltd. India |
Mumbai, India |
300 |
Private |
|
Biotoxtech Co Ltd |
Cheongwon, Korea, Republic of |
180 |
Public |
|
Dong-A Socio Holdings Co Ltd |
Seoul, Korea, Republic of |
330 |
Public |
|
Dongwha Pharm Co Ltd |
Seoul, Korea, Republic of |
753 |
Public |
|
Ildong Pharmaceutical Co., Ltd. |
Seoul, Korea, Republic of |
1,386 |
Public |
|
Yuhan Corporation |
Seoul, Korea, Republic of |
1,516 |
Public |
Executive report
|
Board of
Directors |
|
|
|
|
|||
|
Chairman |
Chairman |
|
|||
|
Chairman |
Chairman |
|
|
Executives |
|
|
|
|
|||
|
Vice President |
Senior Management (General) |
|
|||
|
Finance Head |
Finance Executive |
|
Significant Developments
Chongkundang Corp. Announces Change in Shareholding Structure Nov 05, 2013
Chongkundang Corp. announced that Brain Asset Management Co., Ltd. has
purchased 698,465 shares of the Company, representing a 5.35% stake.
Chongkundang Corp. Receives Patent from U.S. Jul 25, 2013
Chongkundang Corp. announced that it has received a patent from the United
States on July 24, 2013, for new preparation of rosuvastatin, the useful
intermediates thereof and preparation of the same.
Chongkundang Corp. Announces Resignation of Co-CEO Jul 02, 2013
Chongkundang Corp. announced that its Co-Chief Executive Officer (Co-CEO), Lee
Jang Han, has resigned from the Company, effective July 2, 2013. The current
Co-CEO, Kim Jeong Wu, continues his duty as Chief Executive Officer at the
Company.
Chongkundang Corp. to Divest Pharmaceutical Business into Subsidiary Jul 01, 2013
Chongkundang Corp. announced that it will divest its pharmaceutical business
into a newly established wholly owned subsidiary. The transaction effective
date and registration date are expected to be November 2, 2013 and November 5, 2013,
respectively.
Chongkundang Corp. Announces Changes in Shareholding Structure Jun 18, 2013
Chongkundang Corp. announced that SAMSUNG ASSET MANAGEMENT and its two related
parties have purchased 653,316 shares of the Company, representing a 5.01% stake.
Chongkundang Corp. Receives Patent from U.S. May 09, 2013
Chongkundang Corp. announced that it has received a patent from the United
States on May 8, 2013, for new hydroxamate derivatives, process for preparing
thereof and pharmaceutical composition containing the same.
Chongkundang Corp. Declares Annual Cash Dividend for FY 2012 Feb 27, 2013
Chongkundang Corp. announced that it has declared an annual cash dividend of
KRW 700 per share of common stock to shareholders of record on December 31,
2012, for the fiscal year 2012. The dividend rate of market price is 2.04% and
the total amount of the cash dividend is KRW 8,530,246,200.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.07 |
|
UK Pound |
1 |
Rs.103.61 |
|
Euro |
1 |
Rs.85.03 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or
its officials.